1987
DOI: 10.1097/00000542-198709001-00353
|View full text |Cite
|
Sign up to set email alerts
|

Dose-Duration Relationship of Bu1090u by Bolus Injections

et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
1
0

Year Published

1988
1988
1989
1989

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 0 publications
1
1
0
Order By: Relevance
“…Throughout the study period, anaesthetic depth, temperature and endtidal Pco 2 remained stable and the patients received no additional drugs which would interact with the mivacurium. The increasing time interval between doses was a surprising finding, because no evidence of cumulation has been found with mivacurium in other studies [1,7]. However, in these other investigations, fewer doses of mivacurium were administered than in the present study.…”
Section: Discussionsupporting
confidence: 41%
“…Throughout the study period, anaesthetic depth, temperature and endtidal Pco 2 remained stable and the patients received no additional drugs which would interact with the mivacurium. The increasing time interval between doses was a surprising finding, because no evidence of cumulation has been found with mivacurium in other studies [1,7]. However, in these other investigations, fewer doses of mivacurium were administered than in the present study.…”
Section: Discussionsupporting
confidence: 41%
“…Mivacurium chloride (BW B1090U), a new shortacting non-depolarizing neuromuscular blocking drug, has undergone initial clinical trials to evaluate its neuromuscular and cardiovascular effects [1][2][3][4][5][6][7]. Mivacurium is metabolized by pseudocholinesterase at a rate 70% of that of suxamethonium [8].…”
mentioning
confidence: 99%